CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy

Ferrara, Felicetto; Morabito, Fortunato; Martino, Bruno; Specchia, Giorgina; Liso, Vincenzo; Nobile, Francesco; Boccuni, Piernicola; Noto, Rosa Di; Pane, Fabrizio; Annunziata, Mario; Schiavone, Ettore Mariano; Simone, Mariacarla De; Guglielmi, Cesare; Vecchio, Luigi Del; Coco, Francesco Lo

doi:10.1200/jco.2000.18.6.1295

Cited by 154 publications

(118 citation statements)

References 31 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…39 Although it is reported from time to time that CD56 expression in patients with APL may be an independent factor predicting poor prognosis, further confirmation is needed. 40,41 We agree with the views of Sanz et al 42 that three simultaneous actions should be done when a diagnosis of APL is suspected: the start of ATRA therapy before confirmation of the diagnosis; institution of supportive measures; and rapid confirmation of genetic diagnosis. As Tallman et al 5 mentioned, bleeding is the most dangerous complication and represents a major cause of early death (ED) for the newly diagnosed APL patients.…”

Section: Initial Approach For Suspected Aplsupporting

confidence: 80%

How to manage acute promyelocytic leukemia

et al. 2012

Leukemia

View full text Add to dashboard Cite

Section: Initial Approach For Suspected Aplsupporting

confidence: 80%

How to manage acute promyelocytic leukemia

et al. 2012

Leukemia

View full text Add to dashboard Cite

“…Written informed consent was obtained in all cases. Diagnosis was based on the WHO classification criteria using standard morphology and cytochemistry [23] and confirmed in all cases by immunophenotypic analysis as previously described [24]. Clinical and haematological characteristics of patients are summarized in Table 1.…”

Section: Methodsmentioning

confidence: 99%

Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan

Ferrara

Palmieri

Pedata

et al. 2009

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

Different studies have suggested the potential utility of autologous stem cell transplantation (ASCT) in acute myeloid leukaemia (AML) of the elderly with encouraging results in selected patients. However, while the introduction of peripheral blood stem cells (PBSC) has consistently reduced morbidity and mortality of the procedure, relapse still represents the major cause of ASCT failure. One possibility to ameliorate therapeutic results could rely on the adoption of conditioning regimens specifically designed for AML. We report therapeutic results from a series of 40 AML patients older than 60 years (median age 67 years) autografted in first complete remission (CR), after conditioning with continuous infusion (c.i.) high dose idarubicin and busulphan. Fourty patients (median age: 67 years) received 2 days c.i. idarubicin at 20 mg/m 2 /day, followed by 3 days oral or intravenous busulphan (4 mg/kg/day) as conditioning. No case of transplant-related mortality occurred. Cardiac toxicity was absent, while 31 patients (77%) had grade 3-4 mucositis. After a median follow-up of 25 months, median disease free and overall survival (OS) for the whole patient population were 13 and 22 months, respectively. Three patients died while in CR from causes unrelated to AML. Better results were achieved in patients with intermediate karyotype as opposed to those with adverse cytogenetics. Our data confirm the feasibility of a conditioning regimen based on high-dose idarubicin plus busulphan in older selected AML patients and suggest clinical improvement in patients with normal cytogenetics.

show abstract

“…It is also found in a subset of CD3+ cytotoxic T-cells, CD4+ T-cells, or monocytes [5]. The expression of CD56 is one of the most adverse risk factors in patients with AML [5][6][7]. Although CD56 expression in AML with t(8;21) has been associated with extramedullary manifestations [8][9][10][11][12] and multidrug resistance [13,14], its clinical and prognostic significance has not been clearly defined.…”

Section: Introductionmentioning

confidence: 99%

Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

et al. 2006

View full text Add to dashboard Cite

CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease-free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56À group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56À group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56À patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J.

show abstract

CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy

Cited by 154 publications

References 31 publications

How to manage acute promyelocytic leukemia

How to manage acute promyelocytic leukemia

Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan

Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

Contact Info

Product

Resources

About